SCHEMBL5457467

SCHEMBL5457467

CC(=O)c1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCSC3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.56
KCNH2 Q12809 10/20 0.51
TNIK Q9UKE5 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
EPHB4 P54760 1/20 0.48
KDM4E B2RXH2 2/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPRA P18433 1/20 0.46
POLB P06746 1/20 0.45
PPARG P37231 1/20 0.45
NR2E3 Q9Y5X4 1/20 0.45
NCOR2 Q9Y618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452256 0.89 TLR2 (0.53) FLT3KCNH2TNIKMEN1KMT2A
SCHEMBL5447105 0.87 KMT2A (0.58) KCNH2TNIKMEN1KMT2ANPC1
SCHEMBL5455850 0.87 FLT3 (0.53) FLT3KCNH2TNIKMEN1KMT2A
SCHEMBL5451319 0.86 KCNH2 (0.52) FLT3KCNH2TNIKMEN1KMT2A
SCHEMBL5453159 0.86 FLT3 (0.55) FLT3KCNH2TNIKNPC1RAB9A
SCHEMBL5453610 0.85 FLT3 (0.77) FLT3MEN1KMT2ANPC1RAB9A
SCHEMBL5451654 0.85 TNIK (0.54) FLT3KCNH2TNIKMEN1KMT2A
SCHEMBL5454155 0.84 KCNH2 (0.49) FLT3KCNH2TNIKMEN1KMT2A
SCHEMBL5453162 0.83 KCNH2 (0.48) KCNH2TNIKMEN1KMT2ANPC1
SCHEMBL5451566 0.83 FLT3 (0.56) FLT3KCNH2TNIKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885KCNH2 3409/4885TNIK 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.